Wire · regulatory
FDA Finds Problems at 49% of Supplement Manufacturing Sites
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
The FDA inspection results for FY 2025 show that 49.1% of dietary supplement manufacturing facilities worldwide received noncompliance letters for failing to meet current Good Manufacturing Practices (cGMPs), with overseas facilities especially in India, Japan, and Brazil showing 100% noncompliance rates.
This Wire brief sits within Fusion42's coverage of Health: Drug Discovery.
◆ ◆ The Wire takeaway
Manufacturers in the dietary supplements market must urgently address manufacturing compliance or risk FDA citations that could limit access to the US market. You need to call out noncompliant suppliers now and audit quality controls to avoid regulatory disruptions.
◆ Coverage
1 source · 11 Sep 2026
◆ Related on Wire
◆ Topics